LY 233053

Cat. No.:	HY-107710
CAS No.:	125546-04-5
Molecular Formula:	$C_8H_{13}N_5O_2$
Molecular Weight:	211.22
Target:	iGluR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	LY 233053 is a potent and competitive NMDA-receptor antagonist with anticonvulsant and antiepileptic efficacy[1][2].
IC_{50} & Target	NMDA Receptor
In Vivo	LY 233053 (0.5 and 5 mg/kg) has no effects on the electroconvulsive threshold but potentiated the anticonvulsant action of all antiepileptics studied[1]. LY 233053 (5 mg/kg) with carbamazepine, diphenylhydantoin, or phenobarbital provides a 50% protection against maximal electroshock, and results in the impairment of long-term memory[1]. LY233053 (intravenous bolus injection;100 mg/kg; administered 5, 30, or 60 minutes after reversible spinal cord ischemia) is effective in limiting ischemic damage, but protection is lost if therapy is not initiated within 60 minutes of injury in New zealand White rabbits[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. 1.K K Borowicz, et al. Competitive NMDA-receptor antagonists, LY 235959 and LY 233053, enhance the protective efficacy of various antiepileptic drugs against maximal electroshock-induced seizures in mice. Epilepsia. 1996 Jul;37(7):618-24.

[2]. K P Madden, et al. Efficacy of LY233053, a competitive glutamate antagonist, in experimental central nervous system ischemia. J Neurosurg. 1992 Jan;76(1):106-10.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA